A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a COVID-19 Vaccine and an Influenza Vaccine Given as a Single Injection in Healthy Adults

This is a Phase 1/2 single-blind study to evaluate the safety, tolerability, and immunogenicity of licensed BNT162b2 (Omi XBB.1.5) and RIV administered together as a single injection (referred to as BNT162b2 [Omi XBB.1.5]/RIV) in healthy adults 50 years of age or older.

The George Washington University Vaccine Research Unit is seeking volunteers who are:

  1. Male or female participants aged 50 years of older
  2. Good general health as determined by medical history, physical examination (only if required), and clinical judgment of the investigator
  3. Have NOT received a COVID vaccine within the last 6 months
  4. Have NOT received a flu vaccine within the last 6 months

Interested? Fill out our interest survey for more information.
 

Sponsor(s)
Pfizer, Inc
Principal Investigator(s)
Elissa Malkin, DO, MPH
Contact Phone Number
Request Information
Address
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.